Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Other Accumulated Expenses (2022 - 2023)

Dianthus Therapeutics has reported Other Accumulated Expenses over the past 2 years, most recently at $279000.0 for Q2 2023.

  • Quarterly results put Other Accumulated Expenses at $279000.0 for Q2 2023, changed N/A from a year ago — trailing twelve months through Jun 2023 was $279000.0 (changed N/A YoY), and the annual figure for FY2022 was $364000.0, changed.
  • Other Accumulated Expenses for Q2 2023 was $279000.0 at Dianthus Therapeutics, up from $224000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for DNTH hit a ceiling of $364000.0 in Q4 2022 and a floor of $224000.0 in Q1 2023.